Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL727185 | 0.82 | CYP1A2 (0.62) | HRH4HRH3MMP2CYP11B1CYP11B2 | |
| SCHEMBL2872833 | 0.80 | CALM1 (0.52) | HRH3 | |
| SCHEMBL14131007 | 0.79 | NOS2 (0.44) | — | |
| SCHEMBL23075432 | 0.79 | HRH4 (0.46) | HRH4HRH3CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL23068338 | 0.79 | CALM1 (0.50) | HRH3 | |
| Hydrochloric Acid SCHEMBL23067815 | 0.77 | HRH4 (0.44) | HRH4HRH3CYP11B1CYP11B2 | |
| SCHEMBL29995759 | 0.76 | CYP11B1 (0.65) | HRH4HRH3CYP11B1CYP11B2CYP1A2 | |
| SCHEMBL177863 | 0.76 | CYP11B1 (0.65) | HRH4HRH3CYP11B1CYP11B2CYP1A2 | |
| SCHEMBL14257669 | 0.76 | CYP1A2 (0.56) | HRH4HRH3MMP2CYP11B1CYP11B2 | |
| Ammonia Solution, Strong SCHEMBL5999508 | 0.74 | CYP11B1 (0.62) | HRH4HRH3CYP11B1CYP11B2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105143207-B | Substituted pyridine and substituted pyrazine compounds as PDE4 inhibitors | 达特神经科学(开曼)有限公司 | 2018-04-24 | — | — | CN | claimed |
| US-20230057341-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20210070744-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | US | disclosed |
| WO-2021046447-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| CN-108299400-A | Substituted pyridine as PDE4 inhibitor and substituted pyrazine compound | 达特神经科学(开曼)有限公司 | 2018-07-20 | — | — | CN | disclosed |
| CN-105143207-B | Substituted pyridine and substituted pyrazine compounds as PDE4 inhibitors | 达特神经科学(开曼)有限公司 | 2018-04-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070744-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIPK1, RIPK2, RIPK3 | HRH4 3174/4885HRH3 2811/4885MMP2 4132/4885 |
| US-20230057341-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIPK1, RIPK2, RIPK3 | HRH4 3174/4885HRH3 2811/4885MMP2 4132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.